Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bevacizumab biosimilar - mAbxience

Next Previous
Search
Drug Profile

Bevacizumab biosimilar - mAbxience

Alternative Names: ALYMSYS; Alymsys; Bevacizumab-maly; Bevax; BEVZ92; Effivia; Elovie; MB02; MB02-DM; MB02-SP; Oyavas

Latest Information Update: 28 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator mAbxience
  • Developer Amneal Pharmaceuticals; mAbxience
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A expression inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cervical cancer; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma
  • Registered Breast cancer
  • No development reported Cancer

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for phase-I development in Cancer(In volunteers) in New Zealand (IV, Infusion)
  • 03 Oct 2022 Launched for Cervical cancer (Metastatic disease, Recurrent) in USA (IV)
  • 03 Oct 2022 Launched for Colorectal cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top